论文部分内容阅读
目的:回顾性分析异基因造血干细胞移植(allo-HSCT)治疗慢性粒-单核细胞白血病(CMML)的疗效。方法:通过观察13例CMML患者在接受allo-HSCT后造血植入、移植物抗宿主病(GVHD)、感染、复发及生存情况,分析allo-HSCT治疗CMML的临床疗效。结果:13例患者中,男性10例,女性3例;中位年龄38(21-50)岁,其中非亲缘相合移植4例,同胞相合移植6例,亲缘单倍体相合移植3例。13例患者全部获得供者型植入,粒系植入中位时间12(11-18)d,巨核系植入中位时间15(10-55)d,其中8例患者发生急性GVHD,中位随访时间13(6-29)个月,总体生存率53.8%,无病生存率53.8%,复发率7.7%。结论:Allo-HSCT可以改善CMML患者的生存,是治疗CMML的有效手段。
Objective: To retrospectively analyze the curative effect of allo-HSCT on chronic myelomonocytic leukemia (CMML). Methods: The clinical efficacy of allo-HSCT in the treatment of CMML was analyzed by observing the hematopoietic engraftment, graft versus host disease (GVHD), infection, recurrence and survival in 13 CMML patients after receiving allo-HSCT. Results: Among the 13 patients, 10 were males and 3 were females. The median age was 38 years (21-50 years). Among them, 4 were non-related matched grafts, 6 were matched by siblings, and 3 were matched by haploid haploidentical transplantation. All 13 patients received donor-type implantation with a median time of 12 (11-18) days for granulocyte implantation and a median of 15 (10-55) days for implantation of megakaryocytes. Eight of the patients developed acute GVHD, The median follow-up time was 13 (6-29) months. The overall survival rate was 53.8%. The disease-free survival rate was 53.8% and the recurrence rate was 7.7%. Conclusion: Allo-HSCT can improve the survival of CMML patients and is an effective treatment for CMML.